Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unless you think that having the best results ever in cervical cancer (GOG) and doubling the OS in canine osteosarcoma is sheer chance, then the drugs work.
"ADXS is way too early stage to invest in, imho..." We're in PIII. I guess your research skills are suspect, imho...
Thanks, Blue. I've to Hans in the past and hee's usually as upfront as he's allowed to be.
Just send her an email and ask your questions. She's very good at responding in a timely manner.
Of course, DOC had nothing to with PETX approval or not. They are in charge of the filings and follow-up.
Advaxis and Amgen may want to step up their game plan now.
Looks like Opdivo may be a good fit with DUAL even though the particular trial below is for oropharyngeal tumors.
https://immuno-oncologynews.com/2017/09/21/esmo-2017-oropharyngeal-cancer-combined-therapy-nivolumab-isa-101-vaccine-improves-response-rates-study-shows/?utm_source=IO+News&utm_campaign=fc3a00ef68-RSS_WEEKLY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_f04c303b86-fc3a00ef68-72345901
So you have proof that they lied about having the best results to date?
I have never been a company or management basher in my posts here but I am disappointed with today's presentation. I wasn't expecting anything truly new but would have liked to hear about any work being done to try and partner HER2 as well as enrollment updates. I suppose if Arantana gets approval for AT-014, that might up the ante a bit. Overall, it was a recap of past updates. Nothing bad but nothing to push the stock up.
I was disappointed he skipped over so much. Don't recall him talking about cash on hand or HER2. He did touch on NEO, HOT and he mentioned active partnership discussion (the part I was most interested in). The only was I see the stock price rising is with a partnership with upfront cash and the filing of the EMA.
Don't recall anything.
I changed the player from Adobe Flash and it worked.
if that's the case, I hope Lombardo mentions it and the advantages it would have.
If that's the case, you may wish to sell and cut your losses.
Email your thoughts to Noelle and/or Tony. They probably won't say if they have submitted but they'll know the investors are aware what the options for faster approval are. Honestly, a number of the trials could have been submitted for AA or at least more quickly into registrational type trials, IMO.
Monday is Tony's big day and a chance to show he's in-charge and knows what he's doing. He must know the last business update helped send the stock into a tailspin and so he'll carefully choose his words. I don't know what new, if any, information he'll have to share. I just hope there are no more delays. A lot of people saw bad news in the last update. I saw a company prioritizing their assets most likely to be relatively near-term successful. I'm all for licensing out some constructs now to avoid any future dilution. I assume that could not just be sprung at the presentation but I hope to see an announcement soon. I am floored at where the PPS is now. I cannot believe, with a product that is cheap to manufacture, safe and efficacious, we sit in the $4's but here we are. I am NOT selling (not that I have anywhere near as much as others here) and picked up some cheap options. Just one piece of good news, such as a partnership, will start the upward momentum. I appreciate all the good comments from knowledgeable, sane posters. Good luck to us!
Did the company put out a PR regarding their presentation at Cantor Fitzgerald next week? They're shown as a participant but I haven't seen what day and time they have.
Appears the NEO and HOT pages have been updated (unless I just don't remember them looking like this).
https://www.advaxis.com/clinical-trials/mine/
https://www.advaxis.com/hot-program/
ADXS. From the PR, "In addition, the company is actively developing an additional product for prostate cancer, currently in preclinical testing, which could complement ADXS-PSA."
Comparing a Listeria based treatment to chemo is comparing apples to oranges. Both have different methods of action. Now combining them for a better, safer, more efficacious treatment could also be on Amgen's mind and an incentive to invest more in Advaxis. Just my own opinion.
New opening:
Senior Director, Program Management
Overview:
The Director/Sr. Director Program Management is a critical position within the Advaxis organization and will be responsible for managing our lead clinical-stage programs in addition to supporting other Business Operations projects.
Responsibilities:
Responsible for overseeing all aspects of the AXAL program (and other lead programs) including the initiation, planning, and execution of all activities required for the successful research, development and approval of products
Lead the cross-functional product core team(s) that develops and implements the operational and strategic plan, and be the main liaison between the core team(s) and the Management Committee
Major contributor to study start up and recruitment activities for lead clinical programs
Lead ad hoc special projects that support overall corporate objectives
Responsible for managing select alliance partnerships related to lead programs
Major contributor to early commercial planning activities
Forecast, and ensure the program is being managed to, an approved budget and timeline
Build collaborative relationships with multiple departments within the company, including but not limited to research and development, nonclinical, manufacturing, clinical, regulatory, medical, medical affairs, legal and finance.
Qualifications:
EXPERIENCE:
Oncology experience with particular experience in clinical operations/clinical development
Experience building relationships and leading cross-functional teams
This individual will regularly interact with executive management on matters concerning program success and corporate strategy
Ability to work in a fast-paced high energy team environment is essential
The ideal candidate is an innovative, resourceful individual with a proven ability to work autonomously and meet deadlines with a high sense of urgency.
I'm glad to see they're focusing on what they will be value-drivers. After the canine data, I had no doubt the company had a winner. They only have so much to spend and I applaud their efforts. If they had done this sooner, I believe we'd be further ahead but it is what it is. Sometimes I feel like a pest. Whenever, I think it's time to have the clinical trials pages updated, I send Noelle a list. She's always been gracious about my "suggestions" and, I believe, she does forward them on. I just try to be proactive. I want my investment here to pay off one day I might be needing one of their treatments at some time. I think they'll have some of the best out there.
I noticed the updating for open clinical sites for AIM2CERV (and possibly others) has been lagging. I believe they will be updated soon. I want all patients to be able to easily find a location, hopefully near them, for possible enrollment.
Then why do they have this?
PRINCETON, N.J., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, welcomed New Jersey Governor Christopher J. Christie and BioNJ President and Chief Executive Officer Debbie Hart on Sept. 9 to celebrate the completion of its new state-of-the-art manufacturing facility and laboratory with a ribbon-cutting event before close to 200 people.
A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/756b5c86-d837-4a11-93cc-513b45f126bb.
Advaxis built out the 30,000-square-foot expansion at its College Road East headquarters to include a clean-room manufacturing and laboratory facility to develop and manufacture clinical-grade products to support Advaxis’ clinical trials and future commercialization of its immuno-oncology therapeutics.
Very well done article.
"Lombardo is no magician." You are correct, he is only a man who's taking the helm here. I don't expect miracles in the first two months. What I do expect going forward, as he's mentioned it several times, is creating shareholder value. That means, to me, an EU deal with possible US rights and licensing out HER2 in a reasonable amount of time. Perhaps DOC was promising more than they could deliver by year's end. I'll take the EU filing and a deal by December. I'd rather them push out the timeline now for the rest then have them constantly miss their own anticipated deadlines.
"As part of its portfolio refinement, the company has determined it will not pursue further clinical study of ADXS-HER2 at this time, but remains open to ISTs or licensing opportunities.'
If they want to license it out, I hope it is for real value. The canine data was extremely favorable.
It appears he's taking steps to rein in costs, "Given the promising early data in head and neck and anal cancers, Advaxis is actively pursuing opportunities to continue development through investigator-sponsored trials (ISTs) or other third-party approaches." "As part of its portfolio refinement, the company has determined it will not pursue further clinical study of ADXS-HER2 at this time, but remains open to ISTs or licensing opportunities."
My take, anyway.
When I talked to Noelle recently, she mentioned Lombardo was in the running. I posted a comment to that effect a few days ago. Obviously, he was busy going over the company's business plan and is now shaping the focus. If the planned pediatric trial is not to be I fel bad for those who, I truly believe, would have benefited, based on the results of the canine trial. Also, the company's plan puts a rest to the rumors we were divorcing AZN, at least for now.
Doesn't look that way.
I think that hit article on Friday is also playing into it.
Gosh darn, I had a few $7.50 call options for this month. Hmm...people trying to keep the price so the strike price doesn't hit?
You might let him know he is confusing two trials, one for high dose vaccine (cervical cancer) and the an@l cancer trial. The PR he is quoting has nothing to do with the a@al trial. Poor guy is confused. Not sure I'd trust his analysis if he can't keep the trials straight.
Agreed!
A bit about Cam...
https://simplywall.st/news/author/cameronbrookes/
Lombardo could actually get the CEO job. He's in the running with everybody else they're considering. Lets just let the man do his (temporary) job for now. I got a prompt response when I sent him an email and he did indeed say creating shareholder value was a top priority. If he can deliver, I don't care about his spelling and grammar.
Volume increasing, also.
Anyone have the $7.50 call options this month?
I was thinking the same thing. Maybe calculated covering to avoid a steep, fast rise in PPS?